Melanotan 2 is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), designed in the 1980s to resist degradation and bind melanocortin receptors with high potency. Laboratory studies use it as a non-selective melanocortin receptor agonist, particularly to examine MC1R, MC3R, MC4R and MC5R signalling in cell lines and animal models. Its stable lactam ring, modified residues and potency make it a common reference ligand in melanocortin pharmacology. This article covers its structure, mechanism, published research areas and the analytical and storage standards needed for reproducible work. It is written for laboratory researchers and gives no guidance on human use.
What is melanotan 2?
Melanotan 2, also written melanotan II, MT-II or MT2, is classified as a synthetic melanocortin receptor agonist. It is a cyclic lactam analogue derived from the core active region of alpha-MSH, the endogenous 13-residue peptide cleaved from the precursor proopiomelanocortin (POMC). The sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Three features distinguish it from the native hormone. The N-terminus is acetylated, norleucine replaces methionine at position 4 to avoid oxidation, and a lactam bridge between the aspartic acid and lysine side chains forms a ring that stabilises the bioactive conformation. The substitution of D-phenylalanine for the native L-form further increases resistance to proteolysis and receptor potency.
The molecular formula is C50H69N15O9, and the molecular weight is approximately 1024 Da for the free peptide. Commercial material is commonly supplied as an acetate salt, so the stated gross weight includes counterions and water, which affects concentration calculations.
The compound arose from work at the University of Arizona in the 1980s, led by Mac Hadley, Victor Hruby and colleagues, who were seeking melanotropin analogues with greater stability and potency than alpha-MSH. An earlier linear analogue, melanotan 1 (NDP-MSH), was described around the same period, and the cyclic lactam series that produced melanotan 2 was reported in the Journal of the American Chemical Society in 1989. Researchers interested in the original chemistry can begin with a PubMed search for the cyclic lactam alpha-melanotropin analogue papers.
Regulatory context matters for any UK buyer. Melanotan 2 is not an authorised medicine in the United Kingdom, and the Medicines and Healthcare products Regulatory Agency (MHRA) has issued public warnings about unlicensed products sold for human use. The compound is relevant here only as a laboratory research material.
Mechanism of action
The five melanocortin receptors, MC1R to MC5R, are class A G protein-coupled receptors that couple primarily to the stimulatory G protein, Gs. Agonist binding activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP) and activates protein kinase A, which phosphorylates downstream targets including the transcription factor CREB. The five subtypes differ in tissue distribution and function, and melanotan 2 is notable because it binds several of them.
At MC1R, expressed on melanocytes, cAMP signalling regulates the synthesis of eumelanin through the transcription factor MITF and the enzyme tyrosinase. At MC3R and MC4R, expressed in the central nervous system, particularly the hypothalamus, signalling is involved in energy homeostasis and other regulatory circuits studied in neuroscience. MC5R is expressed in exocrine tissues and has been studied in relation to secretory functions. Melanotan 2 acts as a potent agonist at MC1R, MC3R, MC4R and MC5R, and it has little activity at MC2R, the ACTH receptor.
This lack of selectivity is the central methodological point. A response seen in a whole animal cannot be attributed to a single receptor without additional tools. Researchers therefore combine melanotan 2 with receptor-selective antagonists, such as the MC3R/MC4R antagonist SHU9119, or use knockout models and receptor-expressing cell lines to separate the contributions of each subtype.
In cell-based work, the mechanism is usually interrogated using HEK293 or CHO cells transfected with a single melanocortin receptor. Readouts include cAMP accumulation assays and reporter gene assays, from which EC50 values are derived. Such experiments show why “dosage” is a molar concentration question in vitro, and why peptide content, salt form and adsorption to plasticware all influence the effective concentration. The prolonged action of cyclic analogues in some assays reflects slow receptor dissociation and resistance to proteases, so incubation time is an important variable to record.
What the research shows
The literature on melanotan 2 is considerable, but much of it reflects pharmacology in rodents and a small number of early clinical investigations that fall outside the scope of laboratory supply. Four areas of work are summarised in general terms below. Readers should consult the primary papers for methods, concentrations and statistics.
The first area is the original structure-activity work. The Arizona group compared the cyclic lactam analogues with alpha-MSH in classical bioassays, notably the frog skin and lizard skin pigment-dispersion assays and in cultured melanoma cells. They reported that the cyclic analogues were considerably more potent and had more prolonged activity than the native hormone. These were bioassay observations in vitro and in amphibian and reptile tissue, and they established the compound as a high-potency tool ligand.
The second area is central melanocortin signalling in rodents. A study by Fan and colleagues in Nature in 1997 used a cyclic melanocortin agonist, MTII, delivered into the brain ventricles of mice, and reported that it reduced food intake, with the effect blocked by the antagonist SHU9119. The authors concluded that central melanocortin receptors participate in the regulation of feeding behaviour in these animals. The finding is a landmark in melanocortin neuroscience, and it is cited here as a description of a rodent experiment only. It tells the reader about receptor pharmacology in the model used, and no inference should be drawn about any effect in people. The primary literature can be located through a PubMed search for MTII feeding studies in rodents.
The third area is behavioural neuroscience in animals. Several research groups have used melanotan 2 and related agonists in rodents to examine melanocortin involvement in sexual behaviour circuits, autonomic function and reward-related pathways. These studies generally administered the peptide by injection or intracerebroventricular infusion, with exposures expressed per kilogram of body weight or as microgram quantities per animal, and the values differ widely by route and species, so they should be taken directly from the primary papers. They are controlled experiments under ethical approval.
The fourth area is pigmentation biology in cell and animal models. Studies in cultured melanocytes and in mice with different MC1R genotypes have used melanocortin agonists to examine how cAMP signalling regulates the balance between eumelanin and pheomelanin, and how MC1R variants alter responsiveness. This work is basic cell biology and genetics.
A common limitation runs through the field. Whole-animal effects can be difficult to assign to a single receptor, doses and routes differ between laboratories, and the material used is not always characterised. Reproducibility therefore depends on knowing the exact identity, purity and content of the peptide, which is the subject of the handling section below.
Research applications
In the laboratory, melanotan 2 serves several overlapping purposes. The most common is as a reference agonist in melanocortin receptor pharmacology, where it is used to characterise receptor signalling, benchmark novel agonists and antagonists, and validate cAMP or reporter assays. Because it activates several subtypes with high potency, it is often used as a positive control against which selective compounds are measured.
A second context is neuroendocrine research in animal models, where it is used with selective antagonists to dissect the contribution of MC3R and MC4R to energy balance, autonomic regulation and behaviour. These experiments require institutional ethical review and, in the United Kingdom, authorisation under the Animals (Scientific Procedures) Act 1986.
A third context is pigmentation and melanocyte biology. Cultured melanocytes and melanoma cell lines are used to study cAMP-driven melanogenesis, MITF regulation and the effect of MC1R variants. The compound provides a stable stimulus that avoids the rapid degradation of native alpha-MSH.
A fourth context is peptide chemistry and analytical science. Cyclic lactam peptides are used as model compounds for developing synthesis strategies, cyclisation chemistry and analytical methods including LC-MS characterisation. Reference samples of defined purity are also used in methods designed to detect melanocortin analogues in seized or unlicensed products, which is a recognised area of forensic and regulatory analysis.
In all these settings, the sensible meaning of exposure is a defined concentration or per-kilogram quantity justified by prior literature and verified by analytical characterisation of the material actually used.
Purity, storage and handling
Synthesising a cyclic lactam peptide is more demanding than assembling a linear chain of equal length. Cyclisation introduces the possibility of linear precursors, dimers, oligomers and incompletely cyclised products, and the D-amino acid and orthogonal protecting groups add further chemistry. Reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 220 nm is the standard method for purity, and receptor pharmacology work generally looks for a main peak of at least 98 per cent. Because the tryptophan residue also absorbs near 280 nm, a second wavelength can reveal impurities that lack aromatic groups. HPLC should always be combined with mass spectrometry to confirm that the observed mass matches the theoretical value of about 1024 Da. A clean chromatographic peak at the wrong mass, such as an uncyclised precursor, is a clean peak of the wrong compound.
A batch-specific certificate of analysis matters because purity and peptide content vary between synthesis runs. The certificate should carry a lot number matching the vial, the HPLC trace or purity value, the observed and theoretical masses, the test date and, ideally, the salt form and net peptide content. Lyophilised powders contain counterions and residual water, so the mass weighed out is not the mass of peptide, and ignoring this introduces systematic errors into any concentration-response comparison.
Because degradation accelerates once the peptide is in solution, and because the tryptophan and histidine residues are susceptible to oxidation, batch-level verification matters more than with more robust small molecules. UK laboratories sourcing melanotan 2 should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and the same documentation standard applies to buyers comparing Peptides UK- where to buy as a search term, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its specification.
Lyophilised melanotan 2 is generally stored at -20°C in a sealed container with desiccant, and many laboratories use -80°C for long-term archives. Vials should reach room temperature before opening so that condensation does not form on the cold powder. After reconstitution, stability falls. Standard practice is to dissolve the peptide in sterile water or a suitable buffer, divide the solution into single-use aliquots and freeze them to avoid repeated freeze-thaw cycles. Refrigerated storage at 2 to 8°C is sometimes used for solutions consumed within days, but the acceptable period should be validated for the assay concerned rather than assumed. Neutral to alkaline pH can accelerate deamidation and other degradation pathways.
Light sensitivity is a secondary but genuine concern. The tryptophan and histidine side chains can undergo photo-oxidation, so amber vials or dark storage are advisable, and prolonged exposure to bright laboratory lighting should be avoided. Peptides also adsorb to glass and some plastics at low concentrations, so low-bind tubes are preferred for dilute working solutions.
Labelling is a final indicator of quality. Clear naming, sequence, molecular weight, lot number, salt form and an unambiguous research-only statement suggest a supplier that understands its market. Wording that implies use in humans is a warning sign and raises regulatory concerns in the United Kingdom.
Frequently asked questions
What is melanotan 2 used for in laboratory research?
It is used as a non-selective melanocortin receptor agonist in cell-based pharmacology and approved animal studies, typically to characterise MC1R, MC3R, MC4R and MC5R signalling. It is a research material only and is not an authorised medicine in the United Kingdom.
What is the difference between melanotan 1 and melanotan 2?
Melanotan 1 (NDP-MSH) is a linear alpha-MSH analogue, while melanotan 2 is a smaller cyclic lactam heptapeptide. Melanotan 2 has a molecular weight of about 1024 Da and binds several melanocortin receptor subtypes, so results from one compound should not be applied to the other.
How should melanotan 2 be stored for research?
Keep lyophilised peptide at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. Allow vials to reach room temperature before opening. After reconstitution, aliquot and freeze the solution to avoid repeated freeze-thaw cycles and prolonged storage in solution.
How can I verify the purity of a melanotan 2 batch?
Request a batch-specific certificate of analysis showing HPLC purity and a mass spectrometry result near 1024 Da, with a lot number matching the vial. For critical work, independent testing by an accredited analytical laboratory confirms identity, purity and net peptide content.
Melanotan 2 is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
